ADMA Biologics Inc (NASDAQ:ADMA) Shares Acquired by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 45.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,870 shares of the biotechnology company's stock after purchasing an additional 14,870 shares during the period. Kornitzer Capital Management Inc. KS's holdings in ADMA Biologics were worth $950,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics in the 4th quarter worth approximately $35,000. Tsfg LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at $51,000. Farther Finance Advisors LLC boosted its stake in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at $84,000. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at $85,000. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Trading Down 4.9%

NASDAQ ADMA traded down $0.86 on Friday, hitting $16.73. 3,840,226 shares of the stock were exchanged, compared to its average volume of 3,659,237. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The stock has a fifty day moving average price of $19.22 and a two-hundred day moving average price of $18.77. The firm has a market capitalization of $3.99 billion, a P/E ratio of 19.68 and a beta of 0.43. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter in the previous year, the company earned $0.08 earnings per share. The firm's revenue was up 40.2% on a year-over-year basis. Research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.